OBJECTIVE: To compare the rates of physical, psychiatric, and suicide-related events in adolescents with MDD treated withfluoxetine alone (FLX), cognitive-behavioral therapy (CBT), combination treatment (COMB), or placebo (PBO). METHOD: Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic measures for specific physical and psychiatric symptoms. Suicidal ideation and suicidal behavior were systematically assessed by self- and clinician reports. Suicidal events were also reanalyzed by the Columbia Group and expert raters using the Columbia-Classification Algorithm for Suicidal Assessment used in the U.S. Food and Drug Administration reclassification effort. RESULTS: Depressed adolescents reported high rates of physical symptoms at baseline, which improved as depression improved. Sedation, insomnia, vomiting, and upper abdominal pain occurred in at least 2% of those treated with FLX and/or COMB and at twice the rate of placebo. The rate of psychiatric AEs was 11% in FLX, 5.6% in COMB, 4.5% in PBO, and 0.9% in CBT. Suicidal ideation improved overall, with greatest improvement in COMB. Twenty-four suicide-related events occurred during the 12-week period: 5 patients (4.7%) in COMB, 10 (9.2%) in FLX, 5 (4.5%) in CBT, and 3 (2.7%) in placebo. Statistically, only FLX had more suicide-related events than PBO (p =.0402, odds ratio (OR) = 3.7, 95% CI 1.00-63.7). Only five actual attempts occurred (2 COMB, 2 FLX, 1 CBT, 0 PBO). There were no suicide completions. CONCLUSIONS: Different methods for eliciting AEs produce different results. In general, as depression improves, physical complaints and suicidal ideation decrease in proportion to treatment benefit. In this study, psychiatric AEs and suicide-related events are more common in FLX-treated patients. COMB treatment may offer a more favorable safety profile than medication alone in adolescent depression.
RCT Entities:
OBJECTIVE: To compare the rates of physical, psychiatric, and suicide-related events in adolescents with MDD treated with fluoxetine alone (FLX), cognitive-behavioral therapy (CBT), combination treatment (COMB), or placebo (PBO). METHOD: Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic measures for specific physical and psychiatric symptoms. Suicidal ideation and suicidal behavior were systematically assessed by self- and clinician reports. Suicidal events were also reanalyzed by the Columbia Group and expert raters using the Columbia-Classification Algorithm for Suicidal Assessment used in the U.S. Food and Drug Administration reclassification effort. RESULTS: Depressed adolescents reported high rates of physical symptoms at baseline, which improved as depression improved. Sedation, insomnia, vomiting, and upper abdominal pain occurred in at least 2% of those treated with FLX and/or COMB and at twice the rate of placebo. The rate of psychiatric AEs was 11% in FLX, 5.6% in COMB, 4.5% in PBO, and 0.9% in CBT. Suicidal ideation improved overall, with greatest improvement in COMB. Twenty-four suicide-related events occurred during the 12-week period: 5 patients (4.7%) in COMB, 10 (9.2%) in FLX, 5 (4.5%) in CBT, and 3 (2.7%) in placebo. Statistically, only FLX had more suicide-related events than PBO (p =.0402, odds ratio (OR) = 3.7, 95% CI 1.00-63.7). Only five actual attempts occurred (2 COMB, 2 FLX, 1 CBT, 0 PBO). There were no suicide completions. CONCLUSIONS: Different methods for eliciting AEs produce different results. In general, as depression improves, physical complaints and suicidal ideation decrease in proportion to treatment benefit. In this study, psychiatric AEs and suicide-related events are more common in FLX-treated patients. COMB treatment may offer a more favorable safety profile than medication alone in adolescent depression.
Authors: Doug Gray; Jennifer Achilles; Trisha Keller; David Tate; Lois Haggard; Robert Rolfs; Calvert Cazier; John Workman; William M McMahon Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-04 Impact factor: 8.829
Authors: Laurence L Greenhill; Benedetto Vitiello; Mark A Riddle; Prudence Fisher; Erin Shockey; John S March; Jerome Levine; Jane Fried; Howard Abikoff; Julie M Zito; James T McCracken; Robert L Findling; James Robinson; Thomas B Cooper; Mark Davies; Elena Varipatis; Michael J Labellarte; Lawrence Scahill; John T Walkup; Lisa Capasso; Jennifer Rosengarten Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-06 Impact factor: 8.829
Authors: Laurence L Greenhill; Benedetto Vitiello; Prudence Fisher; Jerome Levine; Mark Davies; Howard Abikoff; Allan K Chrisman; Shirley Chuang; Robert L Findling; John March; Lawrence Scahill; John Walkup; Mark A Riddle Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-12 Impact factor: 8.829
Authors: M B Keller; N D Ryan; M Strober; R G Klein; S P Kutcher; B Birmaher; O R Hagino; H Koplewicz; G A Carlson; G N Clarke; G J Emslie; D Feinberg; B Geller; V Kusumakar; G Papatheodorou; W H Sack; M Sweeney; K D Wagner; E B Weller; N C Winters; R Oakes; J P McCafferty Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-07 Impact factor: 8.829
Authors: Graham J Emslie; John H Heiligenstein; Karen Dineen Wagner; Sharon L Hoog; Daniel E Ernest; Eileen Brown; Mary Nilsson; Jennie G Jacobson Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-10 Impact factor: 8.829
Authors: Eric A Storch; Regina Bussing; Marni L Jacob; Joshua M Nadeau; Erika Crawford; P Jane Mutch; Dana Mason; Adam B Lewin; Tanya K Murphy Journal: Child Psychiatry Hum Dev Date: 2015-02
Authors: Cynthia A Prows; Todd G Nick; Shannon N Saldaña; Sanjeev Pathak; Chunyan Liu; Kejian Zhang; Zachary S Daniels; Alexander A Vinks; Tracy A Glauser Journal: J Child Adolesc Psychopharmacol Date: 2009-08 Impact factor: 2.576
Authors: Sarah A Crawley; Nicole E Caporino; Boris Birmaher; Golda Ginsburg; John Piacentini; Anne Marie Albano; Joel Sherrill; Dara Sakolsky; Scott N Compton; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; John March; John T Walkup; Philip C Kendall Journal: Child Psychiatry Hum Dev Date: 2014-08
Authors: Betsy D Kennard; Susan G Silva; Taryn L Mayes; Paul Rohde; Jennifer L Hughes; Benedetto Vitiello; Christopher J Kratochvil; John F Curry; Graham J Emslie; Mark A Reinecke; John S March Journal: Am J Psychiatry Date: 2009-01-15 Impact factor: 18.112